I'm in agreement with WAG - it would appear that the only explanation for the delay in awarding ROW rights is down to Acadia and their longer terms plans in their relationship with Neuren.
If Acadia is heavily involved, there would appear to be 3 scenarios.
1. They have made an offer for ROW rights for trofinetide.
2. They have made an offer to Neuren to purchase trofinetide outright off Neuren.
3. As suggested by WAG, they have made an indicative T/O offer to Neuren, who have continued to decline any offer prior to one or all of the current phase 2 results.
While I'd like Neuren to be more transparent with the current situation, I can appreciate why there are not.
However, it would be frustrating in the extreme if we carry on as is for the next 6 months until the first of the trial results is known.
Share Price, page-5733
-
- There are more pages in this discussion • 5,214 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.671B | |||
| Open | High | Low | Value | Volume |
| $20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 81 | $20.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 2214 | 4 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |